Applied Therapeutics (FRA:2UV) Total Liabilities : €28.35 Mil (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Applied Therapeutics Total Liabilities?

Applied Therapeutics's Total Liabilities for the quarter that ended in Dec. 2024 was €28.35 Mil.

Applied Therapeutics's quarterly Total Liabilities increased from Jun. 2024 (€51.45 Mil) to Sep. 2024 (€90.71 Mil) but then declined from Sep. 2024 (€90.71 Mil) to Dec. 2024 (€28.35 Mil).

Applied Therapeutics's annual Total Liabilities increased from Dec. 2022 (€32.38 Mil) to Dec. 2023 (€66.01 Mil) but then declined from Dec. 2023 (€66.01 Mil) to Dec. 2024 (€28.35 Mil).

Applied Therapeutics Total Liabilities Historical Data

The historical data trend for Applied Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Applied Therapeutics Total Liabilities Chart

Applied Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

18.55

24.21

32.38

66.01

28.35

Applied Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															66.01	77.23	51.45	90.71	28.35

Applied Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Applied Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	26.068	+	(2.281	+	-1.3322676295502E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	28.35

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	82.79	-	54.441
	=	28.35

Applied Therapeutics's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	26.068	+	(2.281	+	-1.3322676295502E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	28.35

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	82.79	-	54.441
	=	28.35

Applied Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Applied Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Applied Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Applied Therapeutics Inc (FRA:2UV) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

APLT:USA 2UV:Germany

Address

545 Fifth Avenue, Suite 1400, New York, NY, USA, 10017

Website

https://www.appliedtherapeutics.com

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

Applied Therapeutics Headlines

No Headlines